<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119948">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01541358</url>
  </required_header>
  <id_info>
    <org_study_id>VAR0074</org_study_id>
    <secondary_id>NCI-2012-00138</secondary_id>
    <secondary_id>SU-02162012-9128</secondary_id>
    <secondary_id>23082</secondary_id>
    <nct_id>NCT01541358</nct_id>
  </id_info>
  <brief_title>Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer</brief_title>
  <official_title>Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies fluorine F-18 sodium fluoride positron emission tomography
      (PET)/computed tomography (CT) in diagnosing bone tumors in patients with cancer. Diagnostic
      procedures, such as fluorine F-18 sodium fluoride PET/CT, may help find and diagnose bone
      cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is to use 18F sodium fluoride (fluorine F-18 sodium fluoride)
      PET/CT scanning to detect and characterize lesions in patients who have suspected skeletal
      malignancy. We hypothesize that scanning with 18F-NaF (fluorine F-18 sodium fluoride) is
      more sensitive for skeletal abnormalities and may better characterize lesions than
      conventional imaging.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual and no funding
  </why_stopped>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of lesions with fluorine F 18 sodium fluoride PET/CT in patients who have suspected skeletal malignancy</measure>
    <time_frame>2 hours</time_frame>
    <description>Imaging will take approximately two hours in total.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity of skeletal lesions with fluorine F 18 sodium fluoride PET/CT in patients with suspected skeletal malignancy</measure>
    <time_frame>2 hours</time_frame>
    <description>Imaging will take approximately two hours in total.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of skeletal lesions with fluorine F 18 sodium fluoride PET/CT in patients with suspected skeletal malignancy</measure>
    <time_frame>2 hours</time_frame>
    <description>Imaging will take approximately two hours in total.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Bone Cancer</condition>
  <arm_group>
    <arm_group_label>Diagnostic (fluorine F 18 sodium fluoride PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo fluorine F 18 sodium fluoride PET/CT scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fluorine F 18 sodium fluoride</intervention_name>
    <description>Undergo fluorine F 18 sodium fluoride PET/CT scan</description>
    <arm_group_label>Diagnostic (fluorine F 18 sodium fluoride PET/CT)</arm_group_label>
    <other_name>18 F-NaF</other_name>
    <other_name>F-18 NaF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography/computed tomography</intervention_name>
    <description>Undergo fluorine F 18 sodium fluoride PET/CT scan</description>
    <arm_group_label>Diagnostic (fluorine F 18 sodium fluoride PET/CT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients referred for evaluation of suspected skeletal cancer

          -  Patients must understand and voluntarily sign an informed consent form after the
             contents have been fully explained to them

        Exclusion Criteria:

          -  Patients who cannot complete a PET/CT scan

          -  Pregnant women

          -  Healthy volunteers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Quon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 10, 2013</lastchanged_date>
  <firstreceived_date>February 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Andrew Quon</investigator_full_name>
    <investigator_title>Associate Professor of Radiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sodium Fluoride</mesh_term>
    <mesh_term>Fluorides</mesh_term>
    <mesh_term>Listerine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
